Featured Content

Winston Wong, PharmD
President, W-Squared Group

PCMH Model Narrowed Economic Gap for Cancer Screening

(Medscape Medical News) Feb 18, 2015 - Patient-centered medical homes (PCMHs) may raise cancer screening rates, especially among groups of lower socioeconomic status, researchers have found.

Commentary: The key message of these results is that more comprehensive care coordination will improve quality.



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

U.S. Food and Drug Administration Accepts Biologics Licensing Application For Opdivo (nivolumab) For the Treatment of Advanced Squamous Non-Small Cell Lung Cancer

(MarketWatch) Feb 27, 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the Biologics Licensing Application (BLA) for Opdivo (nivolumab) for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) after prior therapy.
read article »

Biggest U.S. Health Insurer Tightens Rules on Hysterectomy Coverage

(Wall Street Journal) Feb 26, 2015 - UnitedHealth to require doctors to get authorization before performing most types of procedures; decision marks another blow to laparoscopic power morcellator, which can spread hidden cancer.
read article (paid subscription required) »

Zykadia Recommended For Approval in Advanced Non Small Cell Lung Cancer

(EMA) Feb 27, 2015 - The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation for Zykadia (ceritinib).
read press release »

EMA Will Review Amgen/Onyx' Myeloma Drug

(PharmaTimes [UK]) Feb 26, 2015 - The European Medicines Agency has accepted Amgen/Onyx’ Marketing Authorisation Application for Kyprolis (carfilzomib) as a treatment for multiple myeloma.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



PCMH Model Narrowed Economic Gap for Cancer Screening (Medscape Medical News)

The key message of these results is that more comprehensive care coordination will improve quality.posted by: Winston Wong, PharmD

Opinion: First Biosimilar Poised For FDA Approval (Forbes)

Lowering the cost through rebates and other mechanisms? Why not just lower the price? Rebates and other mechanisms,...posted by: Winston Wong, PharmD

Medicare, Medicaid Ready for ICD-10, Report Suggests (Medscape Medical News)

Wasn't that what they said about healthcare.gov?posted by: Winston Wong, PharmD

New Affordable Care Act Initiative to Encourage Better Oncology Care (CMS.gov)

If I recall correctly, this was the white paper proposal that CMS released last July for comments. It will be...posted by: Winston Wong, PharmD

Analysis: High-Cost Blood Cancer Drugs Deliver High Value (ASH)

Value like beauty can often be in the eyes of the beholder. The problem is that value can be seen from many different...posted by: Thomas Marsland, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Bayer has posted 1 new job.

Check out the OBR Job Board here.



COA_AnnualConf_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
AVEO +31.72%
CVM +8.79%
PVCT +4.66%
CNDO -8.21%
ADXS -7.50%
BPTH -7.50%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: March 8, 2015
Company: Novartis / Sandoz
Product: Zarxio™ (filgrastim, EP2006)

Date: March 2015
Company: Nektar Therapeutics
Product: NKTR-102

Date: Q1 2015
Company: Cell Therapeutics
Product: pacritinib

See All OBR Radar items»